International team conducts genomic study of CTLA-4 blockade therapy in metastatic melanoma

Monoclonal antibodies that target cytotoxic T lymphocyte–associated antigen-4 (CTLA-4) have shown great clinical benefit in patients with metastatic melanoma, generating a long-term response in 20 percent of treated cases. Last week , an international team that included researchers from the Ó³»­´«Ã½ released the largest comprehensive genomic study aimed at identifying the factors that determine response to CTLA-4 blockade therapy in melanoma patients.